Core Viewpoint - Kangtuo Medical announced a cash dividend of 0.20 yuan per share (including tax) for the first half of 2025, with key dates for the dividend distribution outlined [1] Summary by Categories Dividend Announcement - The cash dividend of 0.20 yuan per share will be distributed to shareholders [1] - The record date for the dividend is set for October 10, 2025 [1] - The ex-dividend date and the date of cash dividend payment are both scheduled for October 13, 2025 [1]

证券代码：688314 证券简称：康拓医疗 公告编号：2025-038 西安康拓医疗技术股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.20元 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/10/10 | 2025/10/13 | 2025/10/13 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 9 月 16 日的2025年第二次临时股东会审议通 过。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本81,239,172股为基数，每股派发现金 红利0.20元（含税），共计派发现金红利16,247,834.40元。 三、 相关 ...

Group 1: Changshan Pharmaceutical - The company is preparing for clinical trials of Aibennate peptide for weight loss, with no current plans for oral formulation development [1] - Aibennate peptide is a long-acting GLP-1 receptor agonist, developed through chemical modification of exenatide [1] - The marketing preparation includes team building, product knowledge training, and marketing strategy formulation [1] Group 2: Fosun Pharma - Four innovative drugs approved in the first half of the year are expected to gradually increase sales in the coming months [2] - Innovative drug revenue exceeded 4.3 billion yuan, a year-on-year increase of 14.26%, accounting for over 30% of total drug revenue [2] - The company is actively participating in negotiations for the inclusion of its innovative drugs in insurance and national basic medical insurance directories [2] Group 3: Tiantan Biological Products - The company has established an international cooperation department to enhance its global market presence [3] - Products such as tetanus immunoglobulin and rabies immunoglobulin have already been exported [3] - The company is focused on international certification and registration of key products [3] Group 4: Kangtuo Medical - The US-based subsidiary BIOPLATE has launched a local production line for PEEK plates [4] - The company has completed market access in nearly 40 countries and regions [4] - The marketing of "4D bioactive plates" and PEEK fixation systems is underway in the US [4] Group 5: Tailong Pharmaceutical - The company is focusing on the development of modified new drugs across various therapeutic areas including respiratory, digestive, and oncology [5] - Projects in progress include treatments for Alzheimer's disease and schizophrenia [5] Group 6: Heng Rui Pharmaceutical - The HRS-5635 injection has been included in the list of proposed breakthrough therapies [6][7] - Chronic hepatitis B infection affects approximately 257 million people globally, with a significant mortality rate [7] - There is a pressing need for more effective treatments to achieve functional cure for chronic hepatitis B [7]

Group 1 - The core viewpoint of the news is that 康拓医疗 is actively expanding its global presence through its subsidiary BIOPLATE, which is focused on enhancing profitability and market access in various countries [1] - BIOPLATE has significantly reduced its losses in the first half of 2025 compared to the same period last year by improving operational efficiency and diversifying its product line [1] - The company has achieved product market access in nearly 40 countries or regions and plans to expand its team and resources to grow its business scale [1] Group 2 - The PEEK bone plate production line in the United States has officially commenced operations, and the company is actively promoting its products in the market [1] - The management addressed concerns regarding the slight decline in gross margin by implementing aggressive marketing strategies and optimizing production processes to stabilize margins [1] - In the new business areas of oral, thoracic surgery, and maxillofacial repair, the company is expanding its "优贝雅" brand implant system and has acquired equity in 蝾螈生物 to enhance its product offerings in the oral implant market [2]

Group 1 - The core point of the announcement is the resolution of the second extraordinary general meeting of shareholders held by Xi'an Kangtuo Medical Technology Co., Ltd. on September 16, 2025, with no rejected proposals [1][2]. - The meeting was convened by the board of directors and chaired by Chairman Hu Liren, utilizing a combination of on-site and online voting methods, in compliance with the Company Law of the People's Republic of China and the company's articles of association [2][3]. - A total of 9 directors were in office, with 7 attending the meeting, including 4 participating via communication methods, and the board secretary and financial director also attended [3]. Group 2 - Two ordinary resolution proposals were reviewed and approved: the profit distribution plan for the first half of 2025 and the proposal to provide financial assistance to affiliated companies [4][5]. - Both proposals received more than half of the voting rights held by shareholders or their proxies present at the meeting, with separate counting for minority investors [5]. - The meeting was witnessed by lawyers from Guohao Law Firm (Xi'an), who confirmed that the convening and proceedings of the meeting complied with relevant laws and regulations [5].

证券代码：688314 证券简称：康拓医疗 公告编号：2025-037 西安康拓医疗技术股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 9 月 16 日 （二） 股东会召开的地点：西安市高新区毕原一路西段 1451 号西安康拓医 疗技术股份有限公司三楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股 东及其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 52 | | --- | --- | | 普通股股东人数 | 52 | | 2、出席会议的股东所持有的表决权数量 | 52,923,358 | | 普通股股东所持有表决权数量 | 52,923,358 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 65.1451 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 65.1451 ...

国浩律师（西安）事务所 法律意见书 国浩律师（西安）事务所 关于西安康拓医疗技术股份有限公司 2025年第二次临时股东会的 法律意见书 致：西安康拓医疗技术股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）《中华人民共和 国公司法》（以下简称"《公司法》"）等法律、行政法规和规范性文件的规定， 国浩律师（西安）事务所（以下简称"国浩"）接受西安康拓医疗技术股份有限公 司（以下简称"公司"）的委托，指派律师出席公司 2025 年第二次临时股东会（以 下简称"本次股东会"）并对本次股东会的相关事项进行见证，依法出具本法律意 见书。 国浩及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》和 《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经发生 或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了 充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发表的结论 性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律 责任。 本法律意见书仅供公司 2025 年第二次临时股东会之目的使用，本所及经办律师 同意本法律意见书随同 ...

Core Viewpoint - Kangtuo Medical experienced a decline of 5.62% on September 11, with a stock price of 36.43 yuan per share and a total market capitalization of 2.96 billion yuan [1]. Company Overview - Xi'an Kangtuo Medical Technology Co., Ltd. was established on March 14, 2005, and went public on May 18, 2021. The company specializes in the research, production, and sales of three categories of implantable medical devices [1]. - The revenue composition of the company includes: 63.86% from PEEK material neurosurgical products, 22.54% from titanium material neurosurgical products, 10.97% from other products, and 2.62% from supplementary products [1]. Fund Holdings - Dongxing Fund has a significant holding in Kangtuo Medical, with the Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund (020830) holding 6,653 shares, representing 3.51% of the fund's net value, making it the sixth-largest holding [2]. - The fund has reported a floating loss of approximately 14,400 yuan as of the latest data [2]. Fund Manager Information - The fund manager of Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund is Li Bingwei, who has been in the position for 9 years and 93 days. The total asset size of the fund is 352 million yuan [3]. - During Li Bingwei's tenure, the best fund return was 61.7%, while the worst return was -11.19% [3].

Core Viewpoint - The company is preparing for its second extraordinary general meeting of shareholders in 2025, focusing on maintaining order and protecting shareholder rights during the meeting [2][3]. Meeting Guidelines - The meeting will only allow attendance from shareholders, company directors, senior management, and invited personnel, with strict entry regulations for others [2]. - Shareholders must register 30 minutes before the meeting and present necessary documentation to participate [3]. - The meeting will follow a predetermined agenda for discussing and voting on proposals [3][4]. Voting Procedures - Shareholders will have the right to speak, inquire, and vote during the meeting, but must adhere to time limits and order [4][5]. - Voting will be conducted through both on-site and online methods, with results announced post-meeting [6]. Financial Proposals - The company plans to distribute a cash dividend of 2 yuan per 10 shares, totaling approximately 16.25 million yuan, based on its 2025 half-year report [6][7]. - A proposal to provide financial assistance of up to 2 million USD to its associate company, BRANCHPOINT, is also on the agenda, aimed at supporting product development and registration [7][9]. Financial Assistance Details - The financial assistance will be at an interest rate of 5% per annum and is intended to be used for operational funding [9][10]. - The company has a pending investment obligation of 2 million USD to BRANCHPOINT, which can be offset against the financial assistance provided [10].

证券代码：688314 证券简称：康拓医疗 西安康拓医疗技术股份有限公司 2025 年第二次临时股东会会议资料 2025 年 9 月 1 2025 年第二次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大 会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》及 《西安康拓医疗技术股份有限公司章程》（以下简称"《公司章程》"）《西安康 拓医疗技术股份有限公司股东会议事规则》等相关规定，特制定 2025 年第二次 临时股东会会议须知： 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、高级管理人 员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（加盖公章）、 授权委托书等，上述登记材料均需提供复印件一份，个人登记材料复印件须个人 签字，法定代表人证明文件复印件 ...